What long-term trends can investors expect from RGEN's EPS?

**Repligen's EPS is poised for steady growth**, driven by strategic shifts and robust financial performance:

1. **Strategic Acquisition Impact**: The recent acquisition of 908 Devices' desktop portfolio for $70 million in cash is expected to bolster Repligen's future growth. This move complements its existing portfolio, providing additional revenue streams and enhancing customer offerings.
2. **Financial Performance Indicators**: Repligen's fourth-quarter revenue exceeded expectations, with a reported $168 million, up from $167.5 million in the previous year. This growth was driven by strong performances in its Filtration and Analytics franchises.
3. **Growth Outlook**: The company anticipates continued growth, projecting 2025 revenue between $685 million and $710 million, with organic growth of 9.5% to 13.5% and non-COVID revenue growth of 10% to 14%. This outlook is underpinned by increased orders and a growing installed base.
4. **Profitability Expectations**: Repligen's adjusted gross margin is projected to reach the mid-to-high 50% range by 2025, with further expansion anticipated in 2026. This trend suggests improving profitability, which should positively influence EPS.
5. **Market Position and Innovation**: Repligen's focus on bioprocessing equipment and supplies positions it well for continued market growth. Its innovation in products like the RX10 RPM system and Advipure RNA resin contributes to its above-market growth.

In summary, Repligen's strategic moves, strong financial results, and optimistic growth projections indicate a positive outlook for its EPS in the long term. Investors can expect steady growth as the company capitalizes on market opportunities and enhances its product portfolio.